Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 82% Improvement Relative Risk Vitamin D  PROTECT  Prophylaxis  DB RCT Does vitamin D reduce COVID-19 infections? Double-blind RCT 34 patients in Canada (February - May 2021) Fewer cases with vitamin D (not stat. sig., p=0.19) c19early.org Hosseini et al., Research Square, July 2022 Favors vitamin D Favors control

PRevention of COVID-19 with Oral Vitamin D supplemental Therapy in Essential healthCare Teams (PROTECT): Ancillary study of a randomised controlled trial

Hosseini et al., Research Square, doi:10.21203/rs.3.rs-1588325/v1, PROTECT, NCT04483635
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Early terminated prophylaxis RCT for healthcare workers in Canada, showing 0/19 cases with vitamin D prophylaxis vs. 2/15 for control. 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks.
This is the 18th of 29 COVID-19 RCTs for vitamin D, which collectively show efficacy with p=0.0000035.
This is the 88th of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 226 sextillion).
risk of case, 81.9% lower, RR 0.18, p = 0.19, treatment 0 of 19 (0.0%), control 2 of 15 (13.3%), NNT 7.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hosseini et al., 19 Jul 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, preprint, mean age 39.5, 9 authors, study period 8 February, 2021 - 4 May, 2021, dosage 100,000IU day 1, 10,000IU day 7, 10,000IU day 14, 10,000IU day 21, 10,000IU day 28, 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks, trial NCT04483635 (history) (PROTECT). Contact: banafsheh.hosseini@umontreal.ca.
This PaperVitamin DAll
Abstract: PRevention of COVID-19 with Oral Vitamin D supplemental Therapy in Essential healthCare Teams (PROTECT): Ancillary study of a randomised controlled trial Banafsheh Hosseini (  banafsheh.hosseini@umontreal.ca ) University of Montreal: Universite de Montreal Cecile L Tremblay University of Montreal: Universite de Montreal Cristina Longo University of Montreal: Universite de Montreal Shirin Golchi McGill University John White McGill University Caroline Quach University of Montreal: Universite de Montreal Louis-Georges Ste-Marie University of Montreal: Universite de Montreal Robert Platt McGill University Francine Ducharme University of Montreal: Universite de Montreal https://orcid.org/0000-0001-5096-0614 Research Article Keywords: Vitamin D, Hybrid study, Healthcare workers, Randomized controlled trial Posted Date: July 19th, 2022 DOI: https://doi.org/10.21203/rs.3.rs-1588325/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/20 Abstract Background The study objectives were to ascertain the efficacy of vitamin D supplementation in rapidly increasing serum vitamin D and of implementation of a hybrid (virtual and in-person) trial. Methods In a randomised triple-blind controlled trial, healthcare workers were allocated to receive an oral bolus of 100,000 IU with 10,000 IU/week vitamin D 3 or placebo. The co-primary outcomes of this ancillary study were the change from baseline in serum 25-hydroxyvitamin D [(Δ) 25(OH)D] and proportion with vitamin D sufficiency (25(OH)D ≥ 75nmol/L), at endpoint. Adherence to supplements and procedures as well as adverse event rates were documented. Results Thirty-four (19 intervention, 15 control) subjects were randomised, with 28 (41%) virtual visits. After 44.78 ± 11.00 days from baseline, a significant adjusted group difference of 44.2 (34.7, 53.8) nmol/L was observed in the Δ 25(OH)D (95%CI) in favor of supplementation; 77.8% of intervention, and 13.3% of control, patients were vitamin D sufficient (OR:6.11, 95%CI:1.6, 22.9). The adherence to intervention was 94.7% in the intervention and 100% in the control groups. Irrespective of visit type, high adherence was observed in sampling procedures and completion of fortnightly online questionnaire. No adverse events attributable to vitamin D were reported. Conclusion The vitamin D supplementation rapidly and safely raised 25(OH)D levels to sufficient levels for a biological effect. Similarly high adherence to study procedures was observed with virtual and in-person participation. Trial registration: This trial was registered at https://clinicaltrials.gov on July 23, 2020 (#NCT04483635) Background The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been regarded as the largest public health problem in recent decades1. Concurrent with the development of Page 2/20 COVID-19 vaccines, vitamin D supplementation emerged as a potential primary prevention approach to reduce the incidence and severity of SARS-CoV-2 infection. Indeed, a meta-analysis of 27 observational studies showed a higher odds of COVID-19 related hospitalisation and mortality in subjects with vitamin D deficiency than their counterparts2. Several mechanisms support the potential benefits of vitamin D for COVID-19, particularly via its immunomodulatory effects that enhance antiviral immune response and anti-inflammatory properties3. A reduced risk of several infections (such as..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit